We demonstrated that both RVX-208 and PFI-1 treatments had no effect on the CD4, CXCR4 and CCR5 surface expression, suggesting that RVX-208 and PFI-1 do not increase the possibility of de novo HIV-1 infection. This evidence concerns the gene CCR5 and HIV-1 infection.